On Thursday, the U.S. Foodand DrugAdministration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral medication that is manufactured by Bristol Myers Squibb in New Jersey.
Shares of Bristol Myers Squibb (BMY) rose Friday, a day after the Foodand DrugAdministration (FDA) approved the use of what the pharmaceutical firm called the first treatment for ...